drugset
Drugs / Methotrexate
last change 10 days ago re-read 8 days ago

Methotrexate

also known as MTX · HD-MTX · NSC-740 · ADX-2191 · Methotrexate (MTX) · Amethopterin · LDM · Metex() · +22 more

Small molecule targets DHFR via inhibition

Developed for
rheumatoid arthritis · lymphoma · leukemia · acute lymphoblastic leukemia · primary central nervous system lymphoma · breast cancer · psoriasis · central nervous system neoplasm
+258 more · lymphoblastic lymphoma · urinary bladder cancer · diffuse large B-cell lymphoma · myelodysplastic syndrome · non-Hodgkin lymphoma · central nervous system non-hodgkin lymphoma · female breast carcinoma · graft versus host disease · osteosarcoma · B-cell acute lymphoblastic leukemia · Crohn disease · psoriatic arthritis · adult acute lymphoblastic leukemia · renal pelvis/ureter urothelial carcinoma · Burkitt lymphoma · extranodal nasal NK/T cell lymphoma · HIV infectious disease · Hodgkins lymphoma · neoplastic meningitis · sarcoma · acute graft versus host disease · acute leukemia · ankylosing spondylitis · B-cell non-Hodgkin lymphoma · childhood acute lymphoblastic leukemia · colorectal cancer · ectopic pregnancy · uveitis · acute promyelocytic leukemia · atopic eczema · bladder transitional cell carcinoma · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · gestational trophoblastic neoplasm · gout · infiltrating bladder urothelial carcinoma · intraocular lymphoma · mantle cell lymphoma · proliferative vitreoretinopathy · urethra cancer · acute myeloid leukemia · B-cell childhood acute lymphoblastic leukemia · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · brain cancer · cancer · central nervous system cancer · cirrhosis of liver · disease related to hematopoietic stem cell transplant · head and neck cancer · head and neck squamous cell carcinoma · Langerhans cell histiocytosis · lymphoid leukemia · malignant leptomeningeal tumor · metastatic malignant neoplasm in the brain · ovarian cancer · peripheral T-cell lymphoma, not otherwise specified · precursor B-cell acute lymphoblastic leukemia · urinary bladder carcinoma · urothelial carcinoma · anaplastic large cell lymphoma · atypical teratoid rhabdoid tumor · B-cell adult acute lymphocytic leukemia · bone sarcoma · CD4+/CD56+ hematodermic neoplasm · cerebral ventricle cancer · childhood ependymoma · coronary artery disorder · COVID-19 · estrogen-receptor negative breast cancer · estrogen-receptor positive breast cancer · granulomatosis with polyangiitis · Her2-receptor negative breast cancer · high grade B-cell lymphoma · hydatidiform mole · juvenile dermatomyositis · juvenile idiopathic arthritis · leukemia, myeloid, accelerated-phase · malignant pleural mesothelioma · malignant tumor of meninges · medulloblastoma · multiple sclerosis · myelofibrosis · neuroblastoma · non-small cell lung carcinoma · post-transplant lymphoproliferative disease · precursor lymphoblastic lymphoma/leukemia · progesterone-receptor negative breast cancer · progesterone-receptor positive breast cancer · schizophrenia · systemic sclerosis · T-cell acute lymphoblastic leukemia · T-cell large granular lymphocyte leukemia · T-lymphoblastic lymphoma · Takayasu arteritis · tubal pregnancy · ureter cancer · vitiligo · acquired polycythemia vera · acute leukemia of ambiguous lineage · acute myeloid leukemia, t(15;17)(q24;q21) · aggressive NK-cell leukemia · AIDS-related primary central nervous system lymphoma · ALK-negative anaplastic large cell lymphoma · alopecia areata · anaplastic/large cell medulloblastoma · angioimmunoblastic T-cell lymphoma · anterior urethra cancer · aortitis · aplastic anemia · arteritis · arthritic joint disease · atherosclerosis · atherosclerotic cardiovascular disease · autoimmune disease · B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma · B-lymphoblastic leukemia/lymphoma with hypodiploidy · bladder mixed adenocarcinoma · bladder squamous cell carcinoma · bone osteosarcoma · breast carcinoma · bullous pemphigoid · cardiac sarcoidosis · cardiovascular disorder · central serous chorioretinopathy · cervical cancer · childhood malignant neoplasm · childhood medulloblastoma · chondrocalcinosis · choriocarcinoma · choroid plexus neoplasm · chronic graft versus host disease · chronic lymphoproliferative disorder of NK-cells · connective and soft tissue neoplasm · cutaneous neuroendocrine carcinoma · desmoid tumor · desmoplastic/nodular medulloblastoma · diabetic macular edema · diabetic retinopathy · disease of orbital part of eye adnexa · embryonal tumor with multilayered rosettes · endocrine exophthalmos · enteropathy-associated T-cell lymphoma · eosinophilic fasciitis · eosinophilic granulomatosis with polyangiitis · Epstein-Barr virus-associated lymphoproliferative disorder · erythema nodosum · essential thrombocythemia · extragonadal germ cell tumor · germ cell tumor · glycogen storage disease II · granulomatous mastitis · heart failure · hemophagocytic syndrome · hepatosplenic T-cell lymphoma · HER2 positive breast carcinoma · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · hydrarthrosis · hypopharyngeal carcinoma · hypophosphatasia · infiltrating bladder urothelial carcinoma sarcomatoid variant · infiltrating bladder urothelial carcinoma, clear cell variant · inflammatory bowel disease · intermediate uveitis · interstitial lung disease · invasive breast carcinoma · invasive hydatidiform mole · Langerhans cell histiocytosis specific to childhood · laryngeal carcinoma · leprosy · macular retinal edema · malaria · malignant testicular germ cell tumor · mature T-cell and NK-cell non-Hodgkin lymphoma · medulloblastoma SHH activated and TP53 wild-type · medulloblastoma with extensive nodularity · micropapillary variant infiltrating bladder urothelial carcinoma · microscopic polyangiitis · mixed phenotype acute leukemia · myelitis · myocardial infarction · myocardial ischemia · neoplasm of mature B-cells · neoplasm of mediastinum · nested variant infiltrating bladder urothelial carcinoma · neuritis · neurofibromatosis type 1 · oligoarticular juvenile idiopathic arthritis · optic neuritis · oral cavity carcinoma · oropharyngeal carcinoma · osteoarthritis · osteoarthritis, knee · ovarian carcinoma · phenylketonuria · Philadelphia-positive myelogenous leukemia · plasma cell neoplasm · plasmacytoid variant infiltrating bladder urothelial carcinoma · pleural neoplasm · polyarteritis nodosa · polyarticular arthritis · polyarticular juvenile idiopathic arthritis · posterior urethra cancer · posterior uveitis · primary mediastinal large B-cell lymphoma · primary pulmonary vein stenosis · pulmonary sarcoidosis · reactive arthritis · relapsing polychondritis · relapsing-remitting multiple sclerosis · retina lymphoma · retinitis pigmentosa · rheumatoid factor-negative juvenile idiopathic arthritis · schizoaffective disorder · schizophreniform disorder · sensorineural hearing loss disorder · skin disorder caused by infection · small intestine cancer · spondyloarthropathy · subcutaneous panniculitis-like T-cell lymphoma · supratentorial primitive neuroectodermal tumor · systemic lupus erythematosus · T-cell adult acute lymphocytic leukemia · T-cell non-Hodgkin lymphoma · temporal arteritis · transitional cell carcinoma · type 1 diabetes mellitus · ulcerative colitis · uterine corpus choriocarcinoma · vasculitis · vulvar lichen sclerosus · adult-onset Still disease · alopecia totalis · alopecia universalis · arthropathy, erosive · breast neoplasm · chikungunya · chronic actinic dermatitis · chronic idiopathic urticaria · chronic urticaria · conjunctivitis · cutaneous lupus erythematosus · dermatomyositis · diffuse cutaneous systemic sclerosis · head and neck carcinoma · head and neck neoplasm · lichen planus · lichen planus, oral · mucous membrane pemphigoid · myasthenia gravis · mycosis fungoides · nasopharyngeal carcinoma · non-infectious anterior uveitis · osteoarthritis, hand · primary cutaneous anaplastic large cell lymphoma · rheumatoid arthritis-associated interstitial lung disease · skin carcinoma · squamous cell carcinoma · synovitis · uterine disorder
Investigated by
National Cancer Institute (NCI) · Children's Oncology Group · M.D. Anderson Cancer Center · Amgen · Hoffmann-La Roche · St. Jude Children's Research Hospital
+598 more · Dana-Farber Cancer Institute · Memorial Sloan Kettering Cancer Center · PETHEMA Foundation · Peking Union Medical College Hospital · SWOG Cancer Research Network · Alliance for Clinical Trials in Oncology · European Organisation for Research and Treatment of Cancer - EORTC · Fred Hutchinson Cancer Center · Brigham and Women's Hospital · Eastern Cooperative Oncology Group · Pfizer · University of California, San Francisco · Bristol-Myers Squibb · Genentech, Inc. · National Institute of Allergy and Infectious Diseases (NIAID) · Qilu Hospital of Shandong University · Seoul National University Hospital · AbbVie · AstraZeneca · Beth Israel Deaconess Medical Center · National Heart, Lung, and Blood Institute (NHLBI) · Peking University People's Hospital · Scottish Cancer Therapy Network · Sun Yat-sen University · Tongji Hospital · Wyeth is now a wholly owned subsidiary of Pfizer · Assistance Publique - Hôpitaux de Paris · Children's Cancer Group, China · International Extranodal Lymphoma Study Group (IELSG) · Massachusetts General Hospital · Nanjing Children's Hospital · Ruijin Hospital · Tianjin Medical University Cancer Institute and Hospital · University of Washington · West China Second University Hospital · Assiut University · Cancer Research UK · Charite University, Berlin, Germany · Children's Cancer and Leukaemia Group · Goethe University · HaEmek Medical Center, Israel · Hospices Civils de Lyon · Institute of Cancer Research, United Kingdom · Medical Research Council · OHSU Knight Cancer Institute · Schering-Plough · Second Affiliated Hospital, School of Medicine, Zhejiang University · Shanghai Children's Medical Center · University of Miami · University of Oxford · University of Sao Paulo General Hospital · Xiangya Hospital of Central South University · medac GmbH · Aldeyra Therapeutics, Inc. · Centocor, Inc. · Children's Hospital Medical Center, Cincinnati · Children's Hospital of Philadelphia · Children's Hospital of Soochow University · Deutsche Krebshilfe e.V., Bonn (Germany) · Eisai Inc. · Eli Lilly and Company · Fudan University · GIMEMA Foundation · H. Lee Moffitt Cancer Center and Research Institute · Henan Cancer Hospital · Incyte Corporation · Indiana University · Institute of Hematology & Blood Diseases Hospital, China · Johann Wolfgang Goethe University Hospital · Merck Sharp & Dohme LLC · NCIC Clinical Trials Group · National Center for Research Resources (NCRR) · National Institutes of Health (NIH) · Northwestern University · all 604 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) JYLAMVO — 2024-10-23 fda.gov ↗
Label expansion US (FDA) METHOTREXATE — 2022-03-10 fda.gov ↗
Label expansions (2) US (FDA) METHOTREXATE PRESERVATIVE FREE — 1988-04-07 – 2021-03-29 fda.gov ↗
Label expansions (2) US (FDA) METHOTREXATE SODIUM — 1988-10-31 – 2020-05-04 fda.gov ↗
Approved EU (EMA) Nordimet — 2016-08-18 europa.eu ↗
Approved US (FDA) METHOTREXATE SODIUM — 1953-12-07 fda.gov ↗

Trials 696 · started per year

today
US approved 1953
EU approved 2016
1
2
9
3
4
10
7
13
11
13
13
17
21
17
19
28
12
21
18
32
20
29
21
23
18
24
18
32
18
19
16
25
24
29
22
15
22
27
18
195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 011 trials
Phase 0 NCT07337434 Dec 2025 → Jun 2026 overdue psoriasis Syeda Sana Zaman Recruiting No outcome recorded
Phase 0 NCT06204614 Jun 2024 → Jul 2028 expected infiltrating bladder urothelial carcinoma Brigham and Women's Hospital Enrolling by invitation No outcome recorded
Phase 0 NCT06038968 Sep 2022 → Nov 2023 diabetic retinopathy Minia University Completed No outcome recorded
Phase 0 NCT06555497 Jan 2022 → Dec 2023 psoriasis Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium Completed No outcome recorded
Phase 0 NCT03719105 Mar 2019 → Dec 2027 expected aggressive NK-cell leukemia New York Medical College Recruiting No outcome recorded
Phase 0 NCT02905110 Oct 2017 → Mar 2022 brain cancer The University of Texas Health Science Center, Houston Completed No outcome recorded
Phase 0 NCT02644044 Jan 2016 → Dec 2017 — Tel-Aviv Sourasky Medical Center Unknown No outcome recorded
Phase 0 NCT01760226 Jan 2013 → Aug 2016 post-transplant lymphoproliferative disease, primary mediastinal large B-cell lymphoma Baylor College of Medicine Completed No outcome recorded
Phase 0 NCT01737671 Dec 2012 → Jan 2018 cerebral ventricle cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 0 NCT00734773 Nov 2008 → ? central nervous system neoplasm, lymphoma Northwestern University Withdrawn No outcome recorded Stop: Business
Phase 149 trials
Phase 1 NCT07446400 Mar → Jun 2026 overdue — Otsuka Pharmaceutical Development & Commercialization, Inc. Recruiting No outcome recorded
Phase 1 NCT07196449 May → Jun 2025 overdue — Seoul National University Bundang Hospital Active not recruiting No outcome recorded
Phase 1 NCT06475235 Oct 2024 → Dec 2026 expected primary central nervous system lymphoma Dana-Farber Cancer Institute Recruiting No outcome recorded
Phase 1 NCT06466798 Jul 2024 → Jul 2027 central nervous system cancer, ependymoma, medulloblastoma Jeffrey Treiber Withdrawn No outcome recorded
Phase 1 NCT06108453 Aug 2023 → Oct 2024 — Seoul National University Bundang Hospital Unknown No outcome recorded
Phase 1 NCT05615012 Nov 2022 → Dec 2023 — Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT05602675 Nov 2022 → Mar 2023 — Eli Lilly and Company Completed No outcome recorded
Phase 1 NCT05533372 Oct 2022 → Nov 2025 overdue rheumatoid arthritis ILAb Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT05135858 Sep 2022 → Jan 2025 primary central nervous system lymphoma Assistance Publique - Hôpitaux de Paris Unknown No outcome recorded
Phase 1 NCT05445440 Sep → Nov 2022 — Bristol-Myers Squibb Completed No outcome recorded
Phase 1/222 trials · 3 met primary · 1 missed
Phase 1/2 NCT07559097 Sep 2025 → Dec 2026 expected malignant leptomeningeal tumor Henan Cancer Hospital Recruiting No outcome recorded
Phase 1/2 NCT06554561 Aug 2024 → Aug 2026 overdue primary central nervous system lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 1/2 NCT06289205 Mar 2024 → Feb 2025 proliferative vitreoretinopathy University of Health Sciences Lahore Unknown No outcome recorded
Phase 1/2 NCT05698147 Aug 2023 → Jun 2026 overdue central nervous system cancer Tong Chen, MD Recruiting No outcome recorded
Phase 1/2 NCT05918718 Jan 2023 → May 2024 ectopic pregnancy Tehran University of Medical Sciences Unknown Missed primary
Phase 1/2 NCT04610567 Oct 2020 → Mar 2021 COVID-19 University of Sao Paulo General Hospital Unknown No outcome recorded
Phase 1/2 NCT04622956 Oct 2020 → Dec 2023 graft versus host disease, hematopoietic and lymphoid cell neoplasm University of Sao Paulo General Hospital Unknown No outcome recorded
Phase 1/2 NCT04352465 May → Jun 2020 COVID-19 Azidus Brasil Unknown No outcome recorded
Phase 1/2 NCT04396223 Feb 2020 → Apr 2025 overdue gestational trophoblastic neoplasm Hospices Civils de Lyon Recruiting No outcome recorded
Phase 1/2 NCT04120350 Aug 2019 → Aug 2022 primary central nervous system lymphoma Peking Union Medical College Hospital Unknown No outcome recorded
Phase 2280 trials · 7 met primary · 6 missed
Phase 2 NCT07812493 Sep 2026 → Sep 2028 expected diffuse large B-cell lymphoma Pengpeng Xu Not yet recruiting No outcome recorded
Phase 2 NCT06290687 Sep → Dec 2026 infiltrating bladder urothelial carcinoma Case Comprehensive Cancer Center Withdrawn No outcome recorded
Phase 2 NCT07643103 Jun 2026 → May 2028 expected precursor B-cell acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT07604987 May 2026 → May 2028 expected primary central nervous system lymphoma Zou Dehui Recruiting No outcome recorded
Phase 2 NCT07124078 May 2026 → Jan 2029 expected chronic graft versus host disease Incyte Corporation Recruiting No outcome recorded
Phase 2 NCT07227584 Apr 2026 → Jul 2030 expected acute lymphoblastic leukemia Dana-Farber Cancer Institute Not yet recruiting No outcome recorded
Phase 2 NCT07410520 Feb 2026 → Dec 2028 expected central nervous system non-hodgkin lymphoma The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
Phase 2 NCT07352917 Jan 2026 → Jan 2027 expected vulvar lichen sclerosus Clinica Dermatologica Arbache ltda Recruiting No outcome recorded
Phase 2 NCT07350850 Dec 2025 → Dec 2028 expected primary central nervous system lymphoma Tongji Hospital Recruiting No outcome recorded
Phase 2 NCT07138898 Dec 2025 → Jan 2028 expected rheumatic disorder NYU Langone Health Recruiting No outcome recorded
Show all 280 trials opens the full record — a long page
Phase 2/322 trials · 2 met primary · 1 missed
Phase 2/3 NCT07168980 Jul 2025 → Jun 2030 expected B-cell non-Hodgkin lymphoma Children's Cancer Group, China Recruiting No outcome recorded
Phase 2/3 NCT07059156 Jun 2025 → Jun 2027 expected adult acute lymphoblastic leukemia Shanxi Bethune Hospital Recruiting No outcome recorded
Phase 2/3 NCT05057130 Jan 2022 → Dec 2024 bone sarcoma, connective and soft tissue neoplasm, osteosarcoma Blokhin's Russian Cancer Research Center Unknown No outcome recorded
Phase 2/3 NCT04628767 Nov 2021 → Sep 2027 expected renal pelvis/ureter urothelial carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2/3 NCT04616872 Oct 2020 → Oct 2022 atherosclerosis, coronary artery disorder University of Sao Paulo General Hospital Unknown No outcome recorded
Phase 2/3 NCT04136262 Nov 2019 → Dec 2022 rheumatoid arthritis Guang'anmen Hospital of China Academy of Chinese Medical Sciences Unknown No outcome recorded
Phase 2/3 NCT03280979 Oct 2017 → Jul 2019 gestational trophoblastic neoplasm Assiut University Unknown No outcome recorded
Phase 2/3 NCT02205762 Nov 2016 → Jul 2026 overdue Langerhans cell histiocytosis North American Consortium for Histiocytosis Active not recruiting No outcome recorded
Phase 2/3 NCT02265770 Jun 2015 → Jun 2028 expected childhood ependymoma Centre Leon Berard Recruiting No outcome recorded
Phase 2/3 NCT02405676 Jan 2015 → Dec 2023 overdue B-cell non-Hodgkin lymphoma Children's Cancer Group, China Active not recruiting No outcome recorded
Phase 3156 trials · 20 met primary · 18 missed
Phase 3 NCT07291102 Jul 2026 → Oct 2034 expected medulloblastoma SHH activated and TP53 wild-type Nationwide Children's Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07678229 Jul 2026 → Dec 2031 expected mature T-cell and NK-cell non-Hodgkin lymphoma Rong Tao Not yet recruiting No outcome recorded
Phase 3 NCT07402876 Feb → Dec 2026 expected intraocular lymphoma Aldeyra Therapeutics, Inc. Recruiting No outcome recorded
Phase 3 NCT06297096 Jul 2025 → Dec 2027 expected interstitial lung disease, systemic sclerosis National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland Recruiting No outcome recorded
Phase 3 NCT07008846 May 2025 → Sep 2026 overdue rheumatoid arthritis Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Active not recruiting No outcome recorded
Phase 3 NCT06615050 Apr 2025 → Jan 2031 expected graft versus host disease Incyte Corporation Recruiting No outcome recorded
Phase 3 NCT06520163 Aug 2024 → Aug 2026 overdue non-Hodgkin lymphoma The Affiliated People's Hospital of Ningbo University Recruiting No outcome recorded
Phase 3 NCT06496178 Jun 2024 → Feb 2028 expected head and neck squamous cell carcinoma Merus B.V. Active not recruiting No outcome recorded
Phase 3 NCT03613181 Dec 2023 → Dec 2024 Her2-receptor negative breast cancer, malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain, neoplastic meningitis Angiochem Inc Unknown No outcome recorded
Phase 3 NCT00488605 Aug 2023 leukemia University of New Mexico Withdrawn No outcome recorded
Show all 156 trials opens the full record — a long page
Phase 490 trials · 10 met primary · 8 missed
Phase 4 NCT07352566 Aug 2026 → Jun 2030 expected atopic eczema, psoriasis University of California, San Francisco Not yet recruiting No outcome recorded
Phase 4 NCT06015750 Jul 2026 → Mar 2030 hypophosphatasia Alexion Pharmaceuticals, Inc. Withdrawn No outcome recorded Stop: Business
Phase 4 NCT07477691 May 2026 → Sep 2027 expected phenylketonuria BioMarin Pharmaceutical Recruiting No outcome recorded
Phase 4 NCT07432386 May → Oct 2026 expected psoriasis Zarmeen Khawar Not yet recruiting No outcome recorded
Phase 4 NCT07459933 Mar → Sep 2026 overdue alopecia areata Jinnah Postgraduate Medical Centre Not yet recruiting No outcome recorded
Phase 4 NCT06578728 Sep 2025 → Jun 2026 psoriasis Weill Medical College of Cornell University Terminated No outcome recorded Stop: Enrollment
Phase 4 NCT06943482 Jul 2025 → Feb 2028 expected granulomatous mastitis National University Hospital, Singapore Not yet recruiting No outcome recorded
Phase 4 NCT06913907 Apr 2025 → Dec 2027 expected rheumatoid arthritis Keio University Recruiting No outcome recorded
Phase 4 NCT06653634 Oct 2024 → Dec 2027 expected juvenile idiopathic arthritis Oslo University Hospital Recruiting No outcome recorded
Phase 4 NCT06498089 Jun 2024 → Jun 2026 overdue Takayasu arteritis Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase not applicable65 trials · 1 met primary
— NCT07443592 Mar 2026 → Mar 2031 expected acute lymphoblastic leukemia PETHEMA Foundation Not yet recruiting No outcome recorded
— NCT07191431 Sep 2025 → Sep 2027 expected central nervous system non-hodgkin lymphoma Ruijin Hospital Recruiting No outcome recorded
— NCT07086924 Jun 2025 → Jun 2026 overdue psoriasis, psoriatic arthritis South Valley University Recruiting No outcome recorded
— NCT06832267 Feb 2025 → Feb 2027 expected primary central nervous system lymphoma Zhejiang Cancer Hospital Recruiting No outcome recorded
— NCT06554470 Aug 2024 → Jul 2025 overdue ectopic pregnancy Tanta University Recruiting No outcome recorded
— NCT06445257 Sep 2023 → Apr 2026 primary central nervous system lymphoma Huai'an First People's Hospital Unknown No outcome recorded
— NCT03775460 Jan 2023 → Sep 2025 overdue erythema nodosum London School of Hygiene and Tropical Medicine Active not recruiting No outcome recorded
— NCT05503875 Jan 2023 → Dec 2027 expected psoriasis Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
— NCT06946407 Dec 2022 → Dec 2027 expected central nervous system non-hodgkin lymphoma FengYan Jin Recruiting No outcome recorded
— NCT05300009 Jun 2022 → Jun 2023 skin disorder caused by infection Assiut University Unknown No outcome recorded
Phase not stated1 trial · 1 met primary
— NCT00517894 — lymphoma Study Group of Medical Tumour Therapy (AGMT) No longer available Met primary
Comparator or background therapy922 trials
Phase 0 NCT07059975 Background Oct 2025 → Oct 2028 expected childhood acute myeloid leukemia Joanna Yi Recruiting No outcome recorded
Phase 0 NCT07261306 Comparator Aug → Dec 2025 overdue psoriasis Lahore General Hospital Recruiting No outcome recorded
Phase 0 NCT07169019 Comparator Aug 2025 → Aug 2026 overdue psoriasis Alexandria University Recruiting No outcome recorded
Phase 0 NCT06949267 Background Jun 2025 → Sep 2026 overdue acute graft versus host disease Ruijin Hospital Not yet recruiting No outcome recorded
Phase 0 NCT06476366 Comparator Jul 2024 → Dec 2025 chronic actinic dermatitis Pak Emirates Military Hospital Completed No outcome recorded
Show all 922 trials opens the full record — a long page

Press releases naming this drug 45 releases

DateIssuerRelease
2025-08-28 Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma aldeyra.com ↗
2025-07-24 Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa aldeyra.com ↗
2025-06-26 Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma aldeyra.com ↗
2024-08-05 Nordic Pharma SAS NORDIMET (methotrexate) Self-Injection Pen now available for Treatment of Rheumatoid Arthritis and Psoriasis/Psoriatic Arthritis in Canada nordicpharma.com ↗
2024-05-22 Eisai Inc. METOJECT® SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR LAUNCHED IN JAPAN eisai.com ↗
2024-05-14 SPH-BIOCAD (HK) Limited SPH Receives Registration Certificate for Methotrexate for Injection sphchina.com ↗
2024-02-15 Eisai Inc. METOJECT® SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR APPROVED IN JAPAN eisai.com ↗
2023-06-28 Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa aldeyra.com ↗
2023-06-21 Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 aldeyra.com ↗
2023-03-02 Aldeyra Therapeutics, Inc. FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma aldeyra.com ↗
2022-11-16 Eisai Inc. METOJECT® SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS eisai.com ↗
2022-10-06 Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy aldeyra.com ↗

Evidence & citations 35 cited values

Every value below carries the sentence it was read from. 1,675 sources stand behind the page.

FieldValueCited text
Known as methotrexate “The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗
1614

“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗

“Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive...” NCT02885610 ↗

“The objective of the study is 1. To investigate the efficacy and safety of a high-dose methotrexate-based induction polychemotherapy regimen combined with Rituximab and...” NCT01458730 ↗

“This is an open-label (physician and participant will know the name of the assigned drug), multi-center, non-randomized, drug/drug interaction study of JNJ-38518168 in...” NCT01450982 ↗

“R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗

“The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate,...” NCT03320642 ↗

“Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous...” NCT02399189 ↗

“R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in...” NCT02836158 ↗

“OBJECTIVE: To evaluate the efficacy of 4 cycles of vinblastine, Adriamycin (doxorubicin), methotrexate, and prednisone (VAMP) in patients with favorable-risk Hodgkin lymphoma...” PMID 22735430 ↗ Jun 2012

“Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide,...” NCT00554164 ↗

Show 1,604 more sources
Known as Abitrexate “Abitrexate” NCT01168219 ↗
Known as ADX-2191 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07402876 ↗
2

NCT05392179 ↗

NCT04136366 ↗
Known as Amethopterin “Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)” NCT01020539 ↗
1

“Amethopterin” NCT02220985 ↗
Known as amethopterin (previous name for MTX) “amethopterin (previous name for MTX)” NCT00658047 ↗
Known as Biodim “Methotrexate Biodim®” NCT03103334 ↗
Known as ddMTX-LDE “Methotrexate carried by a lipid nanoemulsion (ddMTX-LDE)” NCT03516903 ↗
Known as FBL-MTX “The Sponsor is developing folate-based liposomes encapsulating methotrexate (FBL-MTX) as a putative therapy for RA, by intravenous (IV) or subcutaneous (SC) administration.” NCT06565273 ↗
Known as HD-MTX “This Phase II, multi-institutional study evaluates the safety of hospital discharge at higher serum methotrexate (MTX) levels in children, adolescents, and young adults with...” NCT07560826 ↗
9

“Those patients will be randomised to two different treatment schedules of chemotherapy either with VEC or VEC+ high dose methotrexate (VEC +HD-MTX).” NCT02265770 ↗

“HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule” NCT02339350 ↗

“Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma” NCT01176981 ↗

“High-dose Methotrexate (HD-MTX) 3.5 g/m² intravenously over 4 hours on Day 1 of each cycle” NCT07002099 ↗

“High dose methotrexate (HD MTX) 5 gm/m2 IV over 4 hours on Day 1 with leucovorin rescue” NCT00187070 ↗

“high-dose methotrexate (HD-MTX)-based first-line regimens” NCT07350850 ↗

“HDMTX 2 g/m2 IV over 2 hours, every 8 weeks” NCT00187057 ↗

“High-dose Methotrexate (8 gm/m2; HD-MTX)” NCT02422641 ↗

“high-dose methotrexate (HD-MTX)” NCT05398224 ↗
Known as Imutrexate “Conventional DMARDs include methotrexate (Imutrexate®)” NCT06753565 ↗
Known as IT MTX “Iodine-131-labeled Monoclonal Antibody BC8 (anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, ABM; with,...” NCT00002554 ↗
Known as Lantarel “Methotrexate (e.g. Lantarel®, Metex®)” NCT02779114 ↗
Known as LDM “A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery...” NCT01594333 ↗
1

“anti-inflammatory agent commonly used in rheumatoid arthritis (low dose methotrexate (LDM))” NCT02576067 ↗
Known as LDMTX “The AIDS Clinical Trials Group Study A5314 sought to lower inflammation with low-dose methotrexate (LDMTX).” PMID 39287554 ↗ Aug 2024
Known as Metex() “Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses...” PMID 25125973 ↗ Aug 2014
1

“Methotrexate (e.g. Lantarel®, Metex®)” NCT02779114 ↗
Known as Metex() PEN “Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses...” PMID 25125973 ↗ Aug 2014
Known as Methotrexate (MTX) “Methotrexate (MTX)” NCT00932113 ↗
2

“Methotrexate (MTX)” NCT03414502 ↗

“methotrexate(MTX)” NCT03411798 ↗
Known as methotrexate (Rheumatrex and others) “methotrexate (Rheumatrex and others)” NCT00132691 ↗
Known as Methotrexate Injection USP “A Prospective, Randomized, Double-masked, Dosing-frequency-controlled, Multicenter Clinical Trial Evaluating the Safety and Activity of Intravitreally Injected ADX-2191...” NCT07402876 ↗
Known as Methotrexate tablets “Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition” NCT05380934 ↗
Known as Methotrexatum dinatricum “Tested investigational medicinal product: Methotrexate (Methotrexatum dinatricum 2,5 mg tbl.).” NCT00651040 ↗
Known as Metoject() “Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses...” PMID 25125973 ↗ Aug 2014
1

“Methotrexate (Metoject® prefilled pen)” NCT07486843 ↗
Known as Metoject() PEN “Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses...” PMID 25125973 ↗ Aug 2014
Known as MTX “Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months...” NCT01679951 ↗
253

“Cycle 5 - 10 Drug: Methotrexate * Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12...” NCT06646211 ↗

“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗

“This Phase II, multi-institutional study evaluates the safety of hospital discharge at higher serum methotrexate (MTX) levels in children, adolescents, and young adults with...” NCT07560826 ↗

“We will recruit hemodynamically stable women with a confirmed PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed by methotrexate (MTX) for some...” NCT02152696 ↗

“Methotrexate (MTX) is an antimetabolite drug showing a competitive reversible binding concerning natural dihydrofolates and acting as an inhibitor of the...” NCT06554470 ↗

“In another study (Protocol #89-I-18), we evaluated treatment with GC and weekly oral doses of methotrexate (MTX) in 15 patients with Takayasu's arteritis, in whom disease...” NCT00001256 ↗

“This multicenter, randomized, crossover study compared preference, ease of use, acceptability, satisfaction, and safety of repeated subcutaneous (SC) self-administrations with...” PMID 25125973 ↗ Aug 2014

“Seventy-five children with definite JDMS will be enrolled in a 24-month prospective, randomized, multicentered trial comparing 3 treatments: oral prednisone (P), combination of...” NCT00035958 ↗

“OBJECTIVE: Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab...” PMID 28955499 ↗ Sep 2017

“The purpose of the study is to compare the effects of methotrexate (MTX) alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab (IFX) on...” NCT00396747 ↗

Show 243 more sources
Known as MTX (methotrexate) “MTX (methotrexate)” NCT00001880 ↗
1

“MTX (methotrexate)” NCT00602667 ↗